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Abstract
Myelodysplastic morphology of blood cells can be encountered not only in myelodys‐
plastic syndrome (MDS) but also in nonclonal disorders like viral, bacterial, parasitic
infections, juvenile rheumatoid arthritis, polyarteritis nodosa, immune thrombocyto‐
penic purpura (ITP), iron deficiency anemia, megaloblastic anemia, dysgranulopoietic
neutropenia,  congenital  neutropenia,  cases  with  microdeletion  22q11.2,  malignant
lymphoma, after administration of granulocyte colony stimulating factor, chemothera‐
py, steroids, smoking, alcohol, posttransplantation, copper deficiency also, together with
or without cytopenia. Absence of cytogenetic abnormality in 50–70% of cases with MDS,
some overlapping morphological and/or pathophysiological features make it challeng‐
ing to differentiate between MDS and other diseases/disorders like aplastic anemia,
refractory ITP, copper deficiency. Transient genetic abnormalities including monoso‐
my 7 in megaloblastic anemia; increased immature myeloid cells in bone marrow of cases
with  copper,  vitamin B12,  or  folic  acid  deficiency in  the  setting of  cytopenia  and
dysmorphism may also lead to the misdiagnosis of MDS. On the other hand, there are
also cases of transient MDS. In this chapter, a literature is be presented to draw atten‐
tion  of  the  readers  on  the  disorders  that  mimic  MDS.  Additionally,  our  personal
experiences are also be shared. Awareness of disorders mimicking MDS may prevent
over- or underdiagnosis of MDS.
Keywords: secondary myelodysplasia, cell death, cell cycle, transient MDS, apoptosis,
rapid cell senescence
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1. Introduction
Myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by ineffective
hematopoiesis in bone marrow and cytopenias in peripheral blood. It is heterogeneous reflected
by a number of subgroups with different characteristics both in adulthood and childhood [1–11].
A single diagnostic parameter specific to MDS has not been discovered yet, and a considerable
number of patients with MDS lack chromosomal abnormality [1, 4]. Currently, the diagnosis
of MDS is mainly dependent on quantitative and qualitative dysplastic abnormalities [5].
Establishment of special characteristics of dysplasia like the number of dysplastic cell lines,
the percentage of the dysplastic cells, and characteristic megakaryocytes as in del(5q)
syndrome are critical in order to be able to assess which subgroup of MDS the patient fits
according to the World Health Organization (WHO) classification. Because uni- or
multilineage dysplasia may be the only criterion that differentiates the subgroups refractory
cytopenia with unilineage dysplasia (RCUD) and refractory cytopenia with multilineage
dysplasia (RCMD) [1, 5, 6, 10, 11]. Additionally, for the lineage to be considered as dysplastic,
at least 10% of the lineage should display displastic findings [1, 2, 5, 6, 8, 10, 11] both in
adulthood and childhood MDS.
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis
Peripheric blood -Anisocytosis
-Poikilocytosis
-Basophilic stippling
-Nuclear hypolobulation
(pseudo-Pelger-Huet cells)
-Cytoplasmic hypo/agranulation
-Blasts
-Platelet anisocytosis
-Giant platelets
Bone marrow -Nuclear budding
Irregular nuclear edges
Internuclear bridging
-Karyorrhexis
-Multinuclearity
-Nuclear hyperlobulation
-Binuclearity
-Megaloblastic changes
-Ring sideroblasts
-Vacuolization
-Periodic acid-Schiff positivity
-Cytoplasmic inclusions
Incomplete
-Hemoglobinization
-Fringed cytoplasm
-Cytoplasmic bridging
-Anisocytosis
-Nuclear hypolobulation
(pseudo-Pelger-Huet cells)
-Nuclear hypersegmentation
-Irregular hypersegmentation
-Bizarre nuclear shapes
-Decreased granules
-Agranularity
-Pseudo Chediak Higashi granules
-Auer rods
-Micromegakaryocytes
-Nuclear hypolobulation
-Large monolobular forms
-Small binucleated elements
-Dispersed nuclei
-Degranulation
Table 1. Recent definitions of morphological features of myelodysplasia (adulthood) [2, 5].
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Nearly half of which is constituted by refractory cytopenia of childhood (RCC) [4]. Minimal
diagnostic criteria for childhood MDS require fulfillment of at least two of the following
criteria: sustained, unexplained cytopenia (neutropenia, thrombocytopenia, or anemia); at
least bilineage morphologic myelodysplasia; acquired clonal cytogenetic abnormality in
hematopietic cells; increased blast count (>5%) [3].
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis
Abnormality -Megaloblastic changes1
-Lobulated nuclei in erythroblasts
(kidney-shaped, bilobulated,
multilobulated, bizarre irregular
nuclear profile)
-Multinuclearity (two or more
distinctly separated nuclei of the same
or of different sizes)
-Cytoplasmic granules or inclusions2
-Bizarre nuclear shape3
-A- or hypogranularity4
-Nuclear/cytoplasmic (N/C)
asyncrony5
-Pseudo-Pelger anomaly6
-Micromegakaryocytes7
-Small binucleated
megakaryocyte8
-Megakaryocyte with small
round separated nuclei9
-Megakaryocytes with
nonlobated round nucleus10
1Megaloblastic changes: At least 1.5 times the size of a normal poly- or orthochromatic erythroblast with coarse
condensation of chromatin and an increased nuclear-to-cytoplasmic ratio or orthochromatic erythroblasts with
decreased nuclear-to-cytoplasmic ratio and at least double the size of a normal erythrocyte of the same maturational
state.
2Cytoplasmic granules or inclusions: Presence of granules or nuclear fragments that can be definitely differentiated
from ribosomal RNA.
3Bizarre nuclear shape: Abnormal nuclear shape, including irregularly lobulated nuclei of segmented granocytes with
chromatin clumping or large twisted bands, large bands or metamyelocytes, multinuclearity (two distinctly separated
neutrophilic bands or segmented nuclei).
4A- or hypogranularity: Neutrophilic or azurophilic granules should be markedly or completely absent and the
cytoplasm of mature neutrophilic granulocytes has to stain pale blue/gray or translucent in the Romanowsky-Giemza
stain. All maturation stages except blast cells should be affected.
5Nuclear/cytoplasmic (N/C) asyncrony: Mature neutrophilic granulocytes and metamyelocytes with basophilic
cytoplasm and myelocytes with neutrophilic cytoplasm.
6Pseudo-Pelger anomaly: Mature granulocytes with either a centrally located round to ovoid nucleus (monolobated
type) or two round nuclei of similar size connected by a slender chromatin bridge (bilobated type).
7Micromegakaryocytes: Mononucleated megakaryocyte with a size comparable to that of a promyelocyte or less,
lacking features of a blast cell.
8Small binucleated megakaryocyte: Small megakaryocyte with the size of a micromegakaryocyte or slightly larger,
with two round well-separated nuclei.
9Megakaryocyte with small round separated nuclei: Megakaryocytes of any size with multiple, at least three, round
separated nuclei.
10Megakaryocytes with nonlobated round nucleus: Megakaryocytes of normal or reduced size with a nonlobated
round nucleus and a mature granular cytoplasm.
Table 2. Morphological features of myelodysplasia (childhood-EWOG-MDS Group, 2005) [13].
The unilineage dysplasia in RCUD of adult MDS should have lasted for at least 6 months if no
clonal cytogenetic abnormality is found and/or ring sideroblasts are less than 15% [12], so for
these patients a repeated bone marrow examination is recommended after a 6 months’
observation [5].
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The dysplastic changes have been standardized in childhood [13, 14] and adulthood MDS [2,
5, 15, 16] (Tables 1–4) being restricted to three lineages as erythroid, granulocytic, and
megakaryocytic lineages. Although monocytes are rarely affected in MDS, their presence
rather is associated with CMML and AML [5].
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis
Abnormality -Abnormal nuclear
lobulation
-Multinuclear cells
-Nuclear bridges
-Pelger-Huet cells
-Hypo- or agranularity
-Giant bands (in severe
neutropenia, this criteria may
not be complied)
-Megakaryocytes with variable size and separated
nuclei or round nuclei (absence of megakaryocytes
does not rule out RCC)
Table 3. Morphological features of myelodysplasia in refractory cytopenia of childhood (RCC) (WHO, 2008) [14].
Dyserythropoiesis Dysgranulopoiesis Dysmegakaryopoiesis
-Polychromasia
-Cleaves in nuclear membrane
-Pyknosis
-Gigantism
-Punctate basophilia
Neutrophilic lineage
-Macropolycyte (PMNL >14 μm)
-Ring nucleus
-Increase in nuclear chromatin clumping
-Nuclear sticks
-Vacuolated cytoplasm
-Increased granules/giant granules
-Hypergranular promyelocytes
-Increased apoptotic forms
Eosinophilic lineage
-Ring nuclei
-Charcot-Leyden crystals in nucleus
-Basophilic granules
-Megakaryocyte fragments
-Giant granules in thrombocyte
-Bothryoid nucleus in megakaryocytes
-Hypogranulation in megakaryocytes
Table 4. Other parameters for myelodysplasia that were suggested previously but had not been included in the recent
guidelines [15, 16].
On the other hand, myelodysplastic findings in blood cells arise due to any challenge during
the course of normal differentiation and therefore these changes can be encountered not only
in clonal disorders like MDS (primary myelodysplasia), but also in various nonclonal disorders
affecting bone marrow like viral, bacterial, parasitic infections [17–27], autoimmune disorders
(juvenile rheumatoid arthritis, polyarteritis nodosa, systemic lupus erythematosis, immune
thrombocytopenic purpura) [17, 28–32], hemophagocytic histiocytosis (HLH), nutritional
problems (malnutrition, iron deficiency anemia, megaloblastic anemia, copper deficiency,
vitamin D deficiency, hyper vitaminosis A) [27, 33–43], neutropenia (congenital dysgranulo‐
poietic, congenital severe, idiopathic) [32, 44, 45], inherited disorders [27, 46, 47], malign
lymphoma [48], due to effects of drugs and toxins [17, 27, 49–54], during posttransplantation
period [27, 55], and other reasons [27] also and called “secondary myelodysplasia” [27]. These
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findings are neutrophils with nuclear shape, hypoagranulation, abnormal nuclei, cytoplasm
and granulation, anisocytosis, poikilocytosis, microspherocytes, giant thrombocytes, lympho‐
cytes with cytoplasmic protrusions and vacuoles, monocytes with dysmorphic nuclei,
cytoplasmic vacuoles and cytoplasmic protrusions, chromatin clumping, nucleocytoplasmic
asyncrony, interchromatin bridges between erythroid precursors, oligonuclear megakaryo‐
cytes, naked megakaryocyte nuclei and cytoplasm, most of which have been included in the
dysplasia criteria in MDS of childhood [13, 14], and adulthood [2, 15, 16].
While MDS is potentially preleukemic, disorders with secondary myelodysplasia are not
neoplastic or preleukemic and are reversible when the underlying factor is removed [27].
Such cases with additional cytopenia in one or more cell lines, due to transient suppression of
hematopoiesis may erroneously lead the physician to the diagnosis of MDS, especially when
no cytogenetic abnormality can be attained. Additionally, assessment of morphological
abnormalities in MDS is still not completely objective [56], in spite of that a number of
dysmorphic findings were simplified, categorized [2, 13–16] and cut-off values were estab‐
lished [5]. This situation is valid especially for low-risk MDS cases without excess blasts and
any detectable cytogenetic abnormalities. Additionally, necessity to wait without definite
diagnosis and therefore therapy for at least 6 months in cytopenia cases with unilineage
dysplasia [5, 12] is distressing for the patient and the family.
On the other hand, it is also challenging to differentiate cases which present as ordinary aplastic
anemia, refractory immune thrombocytopenic purpura (ITP) [31], chronic neutropenia [44,
45] from MDS [4, 9, 14, 57–60]. Transient MDS or MDS-like disorders with or without [61–70]
chromosomal abnormalities, acute myeloblastic leukemia (AML) cases with low blast cell
count [71] should also be considered for accurate diagnosis. Additionally, it should not be
forgotten that autoimmune disorders may also be a component of MDS itself [72–74] and there
may be cases complying the criteria of other MDS subtypes like idiopathic cytopenia of
undetermined significance (ICUS), idiopathic dysplasia of undetermined significance (IDUS)
[5, 7, 58].
This chapter reviews on these diagnostic problems, in the following order:
• Nonclonal disorders which present as dysplasia and cytopenia
• Cases with hypoplastic bone marrow mimicking hypocellular MDS
• Transient chromosome abnormalities in the setting of cytopenia/spontaneous remission in
MDS
• Mutations in the elderly and other cases
• Acute myeloblastic leukemia
• ICUS-IDUS
• Autoimmune disorders
• Common features in pathogenesis
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• Differential diagnosis
• Conclusion and future recommendations
2. Nonclonal disorders which present as dysplasia and cytopenia
2.1. Viral and bacterial infections
In a pilot and unpublished study that we carried on in our clinic, we compared the dysmorphic
parameters in the neutrophils of patients with viral (n:6; infections: rubella, rubeola, viral
eruption of unknown origin, Ebstain Barr virus infection), bacterial (n:7; infections: preseptal
cellulitis, urinary infection, tonsillitis, maxillary sinusitis, lymphadenitis, otitis media)
infections and those of healthy controls. We found that the neutrophil diameter of those with
bacterial infections; the percentage of pseudo Pelger-Huet cells and irregular distribution of
granules in both viral and bacterial infections; the percentage of chromatin clumping in viral
diseases were higher than the control. These findings showed that nonspecific infections can
also give rise to dysmorphic findings in neutrophils.
In another study, we reported that those with bacterial diseases additionally displayed
comparable diameter, macropolycyte (neutrophils with diameter >14 μm) percentage, bizarre
nucleus, irregular distribution of granules with those of pretreatment ITP who also displayed
myelodysplasia [17].
Striking dyserytropoiesis was reported in tuberculosis [27]. Several viral infections which
closely mimick MDS will be delineated below.
2.1.1. Parvovirus infection
In the literature, there are cases of parvovirus infection, with [19–21] or without [22] immu‐
nodeficiency or chronic hemolytic anemia which transiently or chronically mimicked MDS or
dyserythropoietic anemia [22]. Among them the two [19, 20] are of note.
The reported case of Hasle et al. [19] was an 8-year-old, previously healthy boy who admitted
to the hospital with severe anemia, moderate thrombocytopenia, and granulocytopenia and a
2 weeks’ history of intermittent fever. Physical examination was normal except for pallor. Bone
marrow was hypercellular with marked erythroblastopenia and maturation arrest of the
erythropoietic cell line. No giant pronormoblast and hemophagocytosis was noted. Dysplasia
in myeloid and megakaryocytic lineage was evident. He had increased immunoglobulin (Ig)
M, low IgG, slightly decreased natural killer (NK) cells which reduced during follow-up;
impaired in vitro proliferation of blood mononuclear cells on stimulation.
The patient was assumed as MDS and was administered prednisolon, androgenic steroid,
cyclophosphamid and cyclosporine, IgG infusion and frequent blood transfusions and
developed hemochromatosis and hepatosplenomegaly. Thrombocytopenia deepened;
hemoglobin transiently normalized. Parvovirus antibody studies revealed negative but when
polymerase chain reaction technique became available, serum samples of the previous two
years of the disease course and bone marrow smears were found positive for parvovirus
infection.
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The reported case of Baurmann et al. [20] was a 36-year-old, previously healthy woman who
admitted to the hospital with fever, pancytopenia, and atypical lymphoid cells with dysplastic
hematopoietic changes. She had frank splenomegaly, slightly increased bilirubin, lactate
dehydrogenase (LDH), negative Coombs test. Since the bone marrow was hypocellular with
multiple abnormal megakaryocytes, absence of erythropoiesis and 15% blasts carrying
monocytic and histiocytic characteristics, she was diagnosed as MDS-refractory anemia with
excess blasts (RAEB). A second bone marrow aspiration performed 6 days after admission
revealed hypercellularity, no excess of blasts, erythropoietic hyperplasia with giant proery‐
throblasts, megakaryocytes which were in normal number but still dysplastic.
Parvovirus antibodies and DNA were positive while the serologic tests for other viruses were
negative. Reticulocytosis, spherocytes, increased osmotic fragility test, and persistent subclin‐
ical hemolysis indicated at transient aplastic crisis mimicking MDS-RAEB due to parvovirus
infection in the setting of hereditary spherocytosis.
2.1.2. Cytomegalovirus (CMV) infection
Miyahara et al. [23] reported a 41-year-old, previously healthy man who developed severe
thrombocytopenia with myelodysplastic changes of bone marrow and multiple autoimmune
abnormalities, low CD4/CD8 ratio following CMV infection. The bone marrow aspiration was
hypocellular with decreased megakaryocytes, atypical lymphocytes, and trilineage dysplasia.
After a short-course prednisolone therapy, he improved.
It was suggested that direct CD34+ multipotent stem cells were infected with CMV giving rise
to injury to the bone marrow cells. The inhibitory effect of cytokines [tumor necrosis factor
alpha (TNF-α), interferon gamma (IF-  )] produced by CMV-infected leukocytes and stromal
cells on hematopoiesis and autoimmunity might have been responsible for myelodysplastic
changes and thrombocytopenia.
2.1.3. Human immunodeficiency virus (HIV) infection
At the time of primary infection, transient pancytopenia, lymphocytosis, increased hemato‐
gones, increase in CD8+ lymphocytes, isolated autoimmune thrombocytopenia, anemia,
reticulocytopenia, neutropenia, trilineage myelodysplasia both in the peripheral blood and
bone marrow were reported. Megakaryocytes which were in normal or increased numbers
showed apparent naked nuclei and were occasionally dysplastic [18]. Dysplastic findings were
found increased and erythropoiesis became megaloblastic during antiretroviral therapy.
2.1.4. Hepatitis C virus (HCV) infection
HCV-infected patients frequently had varying degrees of bone marrow dysplasia and patients
with pancytopenia were those who had the most frequent bone marrow abnormalities. In the
cohort of HCV-infected patients, those with hematopoietic malignancy also existed [24].
However, bone marrow was a site where HCV replicated extrahepatically which contributed
to the etiology of HCV-associated neutropenia and thrombocytopenia. Peripheral clearance or
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consumption of platelets might have increased in HCV infection also [75, 76] like in other
abnormalities in infections [77].
2.1.5. Virus infections in MDS
It should not be forgotten that more than 50% of patients with myelodysplasia and chronic
myeloproliferative diseases showed elevated antibody titers against viruses like EBV and
HHV-6 [78].
2.2. Parasitic infections
2.2.1. Visceral leishmaniasis
Yaralı et al. [25] reported seven cases with leishmaniasis all of whom had pancytopenia,
dysplasia in erythroid myeloid, and megakaryocytic lineages. The all qualitative and quanti‐
tative findings disappeared after 2 months’ therapy.
The authors postulated that increased TNF-α which was shown to be associated with increased
macrophages, increased oxidized pyrimidine nucleotides, decreased glutathione concentra‐
tion and presumably reduced clearance of free oxygen radicals might be responsible for
myelodysplasia in visceral leishmaniasis, and other hematological findings.
Dhingra et al. [26] also reported 18 cases with leishmaniasis who had various combinations of
cytopenia with increased bone marrow cellularity. Trilineage myelodysplasia (22%), bone
marrow fibrosis (16.6%), hemophagocytosis (11.1%), and increased iron stores (33.3%) were
evident.
It was thought that infected bone marrow stromal macrophages with leishmania, selectively
enhanced myelopoiesis by granulocyte macrophage colony stimulating factor (GM-CSF) and
TNF-α overproduction, giving rise to hypercellularity and trilineage myelodysplasia. In‐
creased iron stores were attributed to cytokine overproduction which also led to anemia.
2.2.2. Others
Secondary myelodysplasia due to plasmodium falciparum and P. vivax infection was also
reported [27].
2.3. Autoimmune disorders
2.3.1. Juvenile rheumatoid arthritis (JRA)
Yetgin et al. [28] reported myelodysplasia in 17 patients with JRA, none of whom had received
iron, corticosteroids, immunosuppressive drugs, or any transfusions, and none had acute
infection or gross bleeding. Bone marrow of all cases revealed normal along with abnormal
maturation at different levels, like left shift, along with trilineage dysplasia, the most promi‐
nent dysplasia being in myeloid lineage. Increased bone marrow cellularity, fatty changes,
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erythroid hypoplasia, myeloid and mild-moderate megakaryocytic hyperplasia were detected.
They all had anemia, mostly being microcytic; the most had leukocytosis and thrombocytosis.
Figure 1. Dysmorphic hematological features of the peripheric blood smears of the patient ASİ with chronic ITP (a–g),
patient MEY with JRA (h–n), patient TÇ with JRA (o–x). Courtesy of Turk J Med Sci [79]. Neutrophils: Macropolycytes
(neutrophil > 15 μm) (b, c, h, i), hypersegmentation (c), cytoplasmic vacuoles (a), hypogranulation (d, o), cytoplasmic
protrusions with or without granules (h, k), irregular distribution of granules (a, c, j), abnormal nuclei with nucleic
protrusions (q, r), neutrophils with long chromatin between the nuclei (j, o), pseudo Pelger-Huet cells (o, p) Lympho‐
cytes: Cytoplasmic protrusions (e, n, u, v, w). Basophils: Centralization of granules (f), abnormal nuclei and hypogra‐
nulation (x). Monocytes: Abnormal nuclei (g, s, t), cytoplasmic vacuoles (g, s), cytoplasmic protrusion (g). Platelets:
Big or giant platelets (l, m) β-gal staining photographs of the patients. Patient TÇ JRA (y), patient MBY with JRA (z),
patient KÇ with SLE (aa), patient HA with acute ITP (ab), patient ASİ with chronic ITP (ac), control (ad) (×100).
The score of myelodysplastic peripheral blood findings but not those of bone marrow corre‐
lated significantly with CRP and ferritin.
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It was postulated that abnormally regulated cytokines and other local intracellular messengers
by cellular immune system lead to alterations of the microenvironment of bone marrow giving
rise to the myelodysplastic features (Figure 1).
On the other hand, clinicians should keep cautious since rheumatoid arthritis and other
rheumatoid disorders may present as a part of immune abnormalities in MDS also [72–74].
2.3.2. Polyarteritis nodosa (PAN)
Yetgin et al. [29] reported a child with hematopoietic dysplastic characteristics in an 11-year-
old girl with PAN. While her blood smear revealed occasional trilineage dysplasia, her bone
marrow displayed moderate cellularity, fatty changes, and trilineage dysplasia in addition to
blast and blast-like mononuclear cells. She received therapy of methyl prednisolone and
cyclophosphamide and all of the hematologic abnormalities were found to have resolved after
6 months. It was suggested that these dysplastic findings were associated with the primary
inflammatory process and increased cytokines.
2.3.3. Systemic lupus erythematosis (SLE)
Voulgarelis et al. [30] reported bone marrow biopsy and aspiration findings of 40 SLE cases in
comparison with 10 MDS-refractory anemia (RA) cases. The patients had mono-bi- or triline‐
age cytopenia. The bone marrows were hyponormocellular with increased erythroid and
megakaryocytic lineages in the majority of cases. All patients had dyserythropoiesis and
dysmegakaryopoiesis. Dysmyelopoiesis was less striking with a left shifting. While the rate of
dyserythropoiesis and dysmegakaryopoiesis were similar in patients with SLE and MDS-RA
(100% vs 100%), the features of bone marrow biopsy specimens differed in that normo-
hypercellularity and abnormal localization of immature progenitors (ALIP) aggregates were
less but bone marrow necrosis was higher in SLE. Dilated sinuses (20%) were seen in SLE while
no dilated sinus was noted in MDS-RA (0%). Increased reticulin, striking stromal edema, lack
of inflammatory vascular damage and lack of microvascular obstruction by thrombus plugs,
aggregates of T and B lymphocytes with polyclonal immunoglobulin expression were other
striking features of SLE [30]. Specific lupus erythematosus (LE) cells (neutrophils containing
a round, amorphous mass of purple, degraded nuclear material) were reported to be rarely
seen when the bone marrow aspirate is anticoagulated and spreading of films were delayed
[27]. These findings showed that bone marrow was a main target in SLE.
In SLE, it was shown that bone marrow fibroblasts could not produce enough hematopoietic
growth factors and stromal cells of SLE patients failed to support allogenic progenitor cell
growth in culture leading to defective hematopoietic microenvironment and altered cytokine
expression. Additionally, autoreactive lymphocytes in the bone marrow of SLE patients might
have directly caused immune destruction of both stromal cells and hematopoietic cells and
indirectly affected them via releasing pro-inflammatory cytokines like TNF-α [35]. Secondary
dysplastic changes in autoimmune diseases, in particular SLE, were demonstrated to closely
mimick those in HIV [27] (Figure 1).
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MDS (RCC, RCUD, RCMD with
unilineage cytopenia as thrombocytopenia)
Chronic ITP
Increased platelet destruction -Present (peripheral) [81] -Present (intrasplenic) [82]
Thrombocyte life span -Short [81, 91] -Short [82]
Thrombocyte production rate -Decreased [81, 91] -Decreased/normal [82]
Micromegakaryocytes -Present [83] -Present [84]
Naked megakaryocyte nuclei
and megakaryocyte
emperipolesis
-Present (more prominent) [31] -Present (less prominent) [31]
Other dysplastic changes -Present [14, 31] -Present [17, 79]
Megakaryocyte apoptosis -Only in micromegakaryocytes [31, 83]
-Necrosis-like programmed cell death
(mature + immature MKs) [81]
-Stage 3 megakaryocytes (apoptosis/
paraapoptosis) [82]
-No apoptosis [85]
Apoptosis in other cell lines -Apoptosis in all cell lines [86, 87] -Lymphocytes: Resistant to apoptosis [88]
-Granulocytes: No increased apoptosis
[89]
Thrombocyte microparticles
(TMPs)
-Present (TMPs/thrombocyte > normal)
[90]
-Present (TMPs/thrombocyte > normal
both in acute and chronic ITP) [90]
Response to splenectomy -Response in several patients with different
rates* [91, 92]
-Sustained response (70–80%) [93]
*Complete thrombocyte response in 50% (at 3 months) and 33% (at 12–54 months) of patients with short thrombocyte
lifespan (<3.5 days), no transfusion requirement, but sustained neutropenia [91, 92].
Table 5. Characteristics of chronic ITP and MDS with unilineage cytopenia as thrombocytopenia (RCC subgroup of
childhood MDS and RCUD, RCMD in adulthood MDS).
2.3.4. Immune thrombocytopenic purpura
In a previous study, we established neutrophil and eosinophil dysmorphism and increased
macropolycytes in patients with acute and chronic ITP before treatment, in comparison with
normal children. Several dysplastic features increased at the end of mega dose steroid (methyl
prednisolone 30 mg/kg/day × 3 days followed by 20 mg/kg/day for the consecutive 4 days)
therapy but decreased within 1–4 weeks after therapy was stopped. Hyperdiploidy in
neutrophils which developed during steroid therapy normalized 7 days after therapy was
stopped [17]. Dysplastic features were noted in other cell lines too [79].
These findings suggested that not only an intrinsic megakaryocyte proliferative defect giving
rise to deficient platelet production were present in refractory chronic ITP patients but a defect
before or at the level of colony forming unit-granulocyte-erythroid-monocyte-megakaryocyte
(CFU-GEMM) also. The antiplatelet antibodies and the increased cytokines in ITP [80] might
have been effective at this level (Figure 1).
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2.3.4.1. Differentiation between MDS (refractory thrombocytopenia) and chronic ITP
Myelodysplastic syndrome with isolated thrombocytopenia (RCC subgroup of childhood
MDS and RCUD, RCMD, MDS-U subgroups of adulthood MDS) can be masqueraded as
refractory chronic ITP and the accurate diagnosis may be challenging due to close similarities
between the two entities like decreased life span, decreased production rate in thrombocytes,
increased thrombocyte destruction, presence of dysplastic findings in myeloid and megakar‐
yocytic cell lines including micromegakaryocytes, naked megakaryocyte nuclei and megakar‐
yocyte emperipolesis; and additionally megakaryocyte apoptosis, platelet microparticles and
good response to splenectomy in several patients [17, 31, 81–93] (Table 5).
Figure 2. Myelodysplastic findings in a patient with MDS (refractory thrombocytopenia). Courtesy of Ped Hemat On‐
col [31]. Erythroid serie: Interchromatin bridge between erythroblasts (a), spherocytes (b). Neutrophilic serie: Bizarre
nucleus, nuclei with striking chromatin clumping, abnormal projections, cytoplasm with irregular distribution of gran‐
ules and vacuoles (c), nucleocytoplasmic asyncrony (c, d). Eosinophilic serie with micronuclei, cytoplasmic vacuola‐
tion, cytoplasm with both eosinophilic and basophilic granules (e). Monocytic serie with cytoplasmic vacuoles (f).
Blast-like cells (g). Histiocytic serie: Sea-blue histiocyte (h). Mitotic cells: Mitosis in an unknown cell (i). Apoptotic
cells with condensed and fragmented nuclei and condensed cytoplasm (j).
Thrombocyte microparticles per thrombocyte were reported more than normal in both
disorders [90] and the both can benefit from splenectomy although with different success rates
[91–93]. Two of these characteristics can be used to differentiate between the two entities. The
first is that, while megakaryocyte apoptosis in ITP starts at stage 3 (mature) megakaryocyte
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level [82] (or apoptosis does not take place in megakaryocytes of ITP patients [85], megakar‐
yocyte apoptosis in MDS is detected in micromegakaryocyte level [31, 83]. The second is that
while apoptosis takes place in myeloid, lymphoid, and monocytic cell lines in MDS [86, 87],
no increase in apoptosis (in granulocytes and lymphocytes) on the contrary resistance to
apoptosis (in lymphocytes) [88, 89] were reported in ITP (Table 5). We followed a patient with
RCC that mimicked therapy resistant chronic ITP, who developed intracranial hemorrhage
twice but underwent a successful bone marrow transplantation [31] (Figures 2–4).
Figure 3. Dysmorphism in megakaryocytic serie, in a patient with MDS (refractory thrombocytopenia). Courtesy of
Ped Hemat Oncol [31]. Evaluation by light microscopy: Mononuclear megakaryocytes (a, b), megakaryocyte with
ring-shaped nucleus (b), megakaryocytes with nuclei that are being extruded out of the cell (i–k, o), the cytoplasm
which is lobulated (i), basophilic and condensed (i, k), naked megakaryocyte nuclei (f–h) with abnormal nuclear shape
(g–i), macroplatelets (c–e, m), dysmorphic platelets (e, l, m) are seen (×100). Evaluation by transmission electron mi‐
croscopy: Stage I megakaryocyte with large, oval, and intended nucleus and a cytoplasm containing abundant ribo‐
somes and granules. Demarcation system of membranes and granules are abundant in cytoplasm, all of which
indicates nucleocytoplasmic asyncrony. The granules were identified as azurophilic granules (single arrow) and un‐
identifiable, large, oval, and electron lucent, abnormal granules (double arrow) (×10,000) (p) and lots of free ribosomes,
azurophilic (single arrow) and abnormal unidentifiable, large, oval, electron lucent granules (double arrow) with de‐
marcation membranes in the cytoplasm of the same cell (×27,800) (q). A megakaryocyte that shows abundant demarca‐
tion membranes, ribosomes, and granules. The granules are heterogenous as to both size and electron density. A
phagosome (emperipolesis) is also seen (×12,930) (r). A stage I megakaryocyte with double nucleoli and abundant de‐
marcation membranes, abundant azurophilic (single arrow) and unidentifiable, large, oval, electron lucent abnormal
granules (double arrow) (s). Apoptotic stage I megakaryocyte that shows a condensed nuclear fragment and con‐
densed cytoplasm, but mitochondria, mitochondrial crystae, and demarcation membranes are still intact (×16,700) (t).
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Figure 4. Fas, annexin and bcl-2 values in lymphocytes (R1), monocytes (R2), granulocytes (R3) from the bone marrow
of the child with MDS (refractory thrombocytopenia), established by flow cytometry (Coulter Elite). Courtesy of Ped
Hemat Oncol [31].
2.3.5. Autoimmune neutropenia
Although chronic idiopathic and autoimmune neutropenia are considered as benign disorders,
it was reported that the bone marrow of these patients displayed dyserythropoiesis by 55%
and they transformed to clonal hematological diseases including NK expansion, hairy cell
leukemia, myelomonocytic leukemia, and MDS (RCUD, RCMD) within 30 months, with a rate
up to 6.5%. Therefore, these patients should be closely followed up [32].
2.4. Hemophagocytic lymphohistiosis (HLH, hemophagocytic syndrome)
All patients whom we followed in our clinic due to primary or secondary HLH had myelo‐
dysplastic features in addition to cytopenia involving at least two cell lines. The common
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findings in the bone marrow were erythroid hyperplasia, chromatin bridges between erythroid
precursors, multiple nuclei in erythroblasts, mild megaloblastic changes, vacuoles in erythro‐
blasts, myeloid precursors and monocytes, sometimes in thrombocytes; hypogranulation in
neutrophil myelocytes, micromyelocytes, irregular distribution of cytoplasmic granules, large
and sometimes hybrid granules in eosinophils; anisocytosis in thrombocytes including giant
thrombocytes, naked megakaryocyte cytoplasm, megakaryocyte emperipolesis, oligomono‐
nuclear megakaryocytes. These changes were probably due to the cytokine storm that played
the major role in the pathogenesis of HLH (Figure 5).
Figure 5. Myelodysplastic bone marrow findings of two patients with secondary (a, b) and primary (c–o) hemophago‐
cytic histiocytosis (HLH) (personal archives). Megakaryocytes with mononuclear nuclei that have irregular edges and
condensed cytoplasm are seen just after (a) and during (b) the process of extruding the nuclei out of the cell, develop‐
ing naked megakaryocyte cytoplasm and nucleus (a). Bilobed erythroid precursor (c), eosinophil myelocytes with cyto‐
plasmic vacuolation and rare basophilic granules, cytoplasmic protrusion (d), a naked nuclei of an unknown cell (e),
cells or formations with heterogenous morphology consisting of numerous vacuoles with various sizes (f, g, i), indis‐
tinguishable from abnormal trombocytes and detached cytoplasm of hemophagocyting histiocyte (h), hypogranulated
and vacuolated band (h), ringed nuclei in eosinophilic myelocytes (j, k), internuclear chromatin bridge (slightly dim)
(l), cytoplasmic protrusions in basophilic erythroblasts (m), bilobed normoblast (n), cytoplasmic vacuolation in a proer‐
ythroblast (o) (vitamin B12, folic acid, Cu, Zn levels were normal).
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2.5. Nutritional deficiencies
2.5.1. Malnutrition
Mono-, bi-, pancytopenia, and hematopoietic dysplasia were reported in patients with
malnutrition, who were generally deficient in iron, vitamin B12, folate, and trace elements also.
Bone marrow cellularity was reduced with normoblastic dyserythropoiesis. Giant metamye‐
locytes, vacuolation in erythroid and granulocytic precursors, abnormal sideroblasts including
ring sideroblasts [27], hemophagocytosis, necrotic cells, and rarely dysmegakaryocytosis were
reported.
Figure 6. Myelodysplastic bone marrow findings of a child with malnutrition and gelatinous transformation (personal
archives). Basophilic erythroblasts with cytoplasmic protrusions (a) and vacuoles (b), agranular neutrophil (c, i) with
numerous cytoplasmic vacuoles and hypersegmented nucleus (c), hypoagranular neutrophils with hypolobulated nu‐
clei with abnormal protrusions, mild chromatin clumping (d, h), eosinophil with abnormal nucleus, irregular distribu‐
tion of granules (g), eosinophilic band with few basophilic granules distributed irregularly (j), vacolated monocytes (e,
j) and histiocytes (f), degenerating histiocytes (j), hypha and amorphous material representing the gelatinous material
(i, k).
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In anorexia nervosa, severe diseases with cachexia and starvation, acantocytosis in the
peripheral blood, hypocellularity with/without “gelatinous transformation” were noted. In
gelatinous transformation, the fat cells in the bone marrow are lost, and hematopoietic cells
are replaced by extracellular matrix material composed of acid mucopolysaccharide rich in
hyaluronic acid is detected [18, 33]. All the reported cases had anemia, leukopenia ± throm‐
bocytopenia [33, 34], rarely only anemia [35] (Figure 6).
Trilineage dysplasia in peripheric blood of iron deficient patients were reported, being higher
than the control group. In addition, microspherocytes which were observed in 20% of iron-
deficient patients were not noted in the control group [36]. Leukopenia and thrombocytopenia
may accompanied these changes as iron deficiency deepened, making the differential diag‐
nosis between iron deficiency anemia and MDS more difficult. Alcantara et al. [94] showed
that iron supported 11 genes in phorbol myristate acetate-induced HL-60 cell lines which were
involved in critical cell decision points to pursue a differentiation or cell death pathway.
Additionally, increased erythropoietin in iron deficiency anemia might also have activated
hematopoietic lineages. Presence of microspherocytes was attributed to a putative involve‐
ment of Rac1 and Rac2 GTPase, also known as Ras-related C3 botulinum toxin substrates 1
and 2 GTPase deficiency which reportedly altered actin assembly in red cells in mice. Further
factors like cellular metabolic enzyme changes, cell growth and differentiation, and gene
expression regulation might have been involved in the pathogenesis [36].
On the other hand, leukemia cases who were under chemotherapy and had myelodysplastic
features were shown to have hypochromic macrocytes and increased serum iron and ferritin
levels and increased soluble transferrin receptor implying at a disturbance in utilizing iron
(functional iron deficiency) [49].
2.5.2. Megaloblastic anemia
See Section 4.2.
2.5.3. Copper deficiency
Copper is a cofactor of a number of enzymes (cuproenzymes) including those important for
hematologic system like hephaestin, seruloplasmin (ferroxidases) and others like cytochrome
c oxidase, superoxide dismutase 1, extracellular superoxide dismutase, and zyklopen, a new
member of the vertebrate multicopper ferroxidase family
Pregnant and lactating women, premature infants, those with malabsorption, inflammatory
bowel diseases, celiac disease, long lasting diarrhea, short bowel syndrome, those under total
parenteral nutrition, or nutrition through jejunal tube, those who underwent gastric resection,
bariatric surgery; Wilsons’ disease patients who consumed copper-depleting drugs, conditions
with excess zinc are under risk of copper deficiency [37–41].
The most important problem in copper deficiency lays in its diagnosis. It may be misdiagnosed
as MDS or underdiagnosed. The time which lapses until appropriate diagnosis is made was
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reported as approximately 1 year. Early diagnosis is important since therapy after neurological
symptoms have developed is difficult [40].
On the other hand, it is of note that 11 out of 32 MDS patients were found to have copper
deficiency [95].
The most striking hematologic findings in copper deficiency are mono-, bi-, and pancytopenia
[39–41]. Anemia which is the most common hematologic finding (97.5%) in copper deficiency
is generally normochromic or macrocytic but rarely microcytic, being dependent on the
severity of the deficiency. When the activity of copper-dependent enzymes decrease, iron
absorption is expected to be impaired, iron transport across intestinal cells be decreased,
conversion of ferrous iron to the ferric form which is necessary for transport of iron by
transferrin be impaired, conversion of ferric iron to ferrous iron which is necessary for
incorporation of iron into the protoporphyrin molecule during hemoglobin synthesis be
inadequate. The latter defect gives rise to both formation of ring sideroblasts and possibly
erythrocyte membrane defect due to low levels of antioxidant zinc/copper dismutase activity
necessary to convert superoxide-free radicals to hydrogen peroxide [37, 39]. However, the
mechanism of anemia is not fully understood [37].
Copper deficiency MDS
Vacuolization -In erythroid + myeloid lineages
[39]
-In erythroid lineage [39]
Dysmegakaryopoiesis
(nuclear lobulation and
abnormal sizes)
-Not present [39]
-Present [37]
-Generally present [2, 5, 14, 39]
Dysplasia -No [39]
-Bilineage [38]
-Three lineage dysplasia [37]
-Unilineage: RCUD; RARS (erythroid)
-Two or more lineages (RCC, RCMD; MDS-U) [2,
5, 14, 39]
Increased hematogones -Present [37] -Absent [39]
Other -Left shift in myelopoiesis
-Reduced terminally differentiated 
myeloid cells, myeloid arrest [39]
-Erythroid arrest at proerythro
blast stage [37]
-Erythroid hyperplasia (generally) [15]
-Myeloid arrest or left shift (generally in RAEB)
[96]
Ring sideroblast -Present [37–39] -Present only in RARS subgroup [2, 5]
Table 6. Bone marrow findings in copper deficiency in comparison with MDS.
Leukopenia in copper deficiency is together with neutropenia which was reported to be the
most frequent and earliest manifestation of copper deficiency [41]. The neutrophils in pe‐
ripheric blood smear are dysplastic. Impaired and delayed maturation, differentiation and
regeneration of hematopoietic precursor cells, increased destruction of myeloid precursors in
the bone marrow, defective neutrophil egress from the bone marrow, shortened life-span of
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neutrophils, and presence of antibodies to neutrophils are the possible etiologic factors for
neutropenia [39, 41].
The bone marrow is generally hypercellular [40] with increased myeloid and/or erythroid
precursors mimicking myeloid and erythroid arrest, vacuolization in erythroid and myeloid
precursors, increased iron stores, prominent ring sideroblasts, plasma cells in which hemosi‐
derin is incorporated, increased hematogones [37] with [37, 38], without [39] myelodysplasia.
In MDS, generally erythroid hyperplasia [15] is encountered. Myeloid arrest or left shift in
granulopoiesis is seen generally in RAEB subgroup of MDS [96]. Characteristics of MDS and
copper deficiency are summarized in Table 6.
2.5.4. Vitamin D deficiency
Vitamin D has both proliferating and differentiating effect on hematopoiesis [42]. The bone
marrow taken from infants with vitamin D deficiency rickets and anemia showed early signs
of myelofibrosis with increase of reticulin which was reversed by vitamin D treatment [97].
Anemia, thrombocytopenia, hepatosplenomegaly, hypocellularity and increased osteoblast
count in bone marrow, and hematopoietic precursors in spleen aspirates were striking.
Hypochromia, macrocytosis, tear drop cells, young myeloid elements along with nucleated
red blood cells were evident [98]. Dysdifferentiation due to its deficiency might have been
aggravated by coexistent malnutrition in many of several patients.
2.5.5. Hypervitaminosis A
An infant with hypervitaminosis A reportedly had eversible severe anemia, thrombocytope‐
nia, and dyserythropoiesis. It was shown that in overdoses, vitamin A strongly inhibited the
proliferation of multipotent hematopoietic cell line and bone marrow mesenchymal stem cells,
through upregulating p21Cip1 and p27Kip1, cyclin-dependent kinase inhibitors [43].
2.6. Severe congenital neutropenia (SCN)
We, previously detected hematopoietic dysmorphism in congenital neutropenia, their non-
neutropenic parents and one sibling, irrespective to the neutropenia mutation that the patients
had [45, 99]. All the tested patients were negative for molecular genetics of MDS and were
normal in conventional cytogenetics. Apoptosis of lymphocytes, granulocytes [45, 99], and
monocytes [45], of both patients and parents and rapid cell senescence (RCS) in leukocytes of
a few patients and their mothers were established [45, 99]. A substantial portion of cases had
clinical or laboratory evidence of hemorrhagic diathesis and low NK and CD4+ cells.
These findings showed that pluripotent stem cells were involved in SCN irrespective to the
genetic defect and non-neutropenic family members were also affected ([45, 99], study in
submission) and congenital neutropenia and MDS shared the same death types and involved
pluripotent stem cells.On the other hand, it should not be forgotten that MDS can present as
isolated neutropenia (RCC, as refractory neutropenia). In our clinic, we followed a 4-year-old
girl who was admitted to our hospital for chronic neutropenia, but the genetic evaluation
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revealed trisomy 8 and a complex karyotype; while the molecular genetic studies for congenital
neutropenia (HAX1, ELANE, and G6PC3) were negative (unpublished data).
Figure 7. Myelodysplastic bone marrow findings of a 5-year-old patient with ALL who was on chemotherapy and had
coexistent autoimmune hemolytic anemia [100] (personal archives). A Gaucher-like histiocyte that is hemophagocytos‐
ing a cell (a), internuclear chromatin bridge between two erythroblasts (b) (arrow), multinucleated erythroblasts with
various sizes (c, e, g, h), striking megaloblastic changes (d), basophilic stippling (b, e–h).
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2.7. Inherited conditions
Özbek et al. [46] reported myelodysplastic features in myeloid and erythroid cell lines, in 20
patients with microdeletion 22q11.2 (del22q11.2) with slight cytopenia. Their smears showed
dysmorphism in erythroid and myeloid cell lineages, in addition to a few vacuolated plasma‐
toid lymphocytes; monocytic cells mimicking hypogranular myelocytes with cytoplasmic
vacuoles and protrusions and blast-like cells.
Myelodysplasia scores in the myeloid cells and eosinophils and macropolycyte percentages
were higher than those with conotruncal heart defects, viral and bacterial infections, and
healthy children. Genes in the deleted region, like human cell division cycle-related (hCDCrel)
gene was proposed to be responsible for these changes.
Other inherited conditions which present as dyserythropiesis and anemia are congenital
dyserythropoietic anemia, thalassemia, congenital dyserythropoietic porphyria, mitochondri‐
al myopathies, hereditary sideroblastic anemia, homozygous hemoglobin C, heterozygous
unstable hemoglobins, some cases with thiamine-responsive anemia with diabetes and
deafness, homozygote pyruvate kinase deficiency, stress erythropoiesis like severe hemolytic
anemia [100] (Figure 7).
Those who present as dysgranulopoiesis with/without neutropenia are mitochondrial
cytopaties, myelokathexis, and congenital neutropenia [45]. Those with dysmegakaryopoiesis
and thrombocytopenia are inherited thrombocytopenias. Patients with GATA1 mutations
have anemia and neutropenia together with trilineage dysplasia [27]. Patients with mevalonc
aciduria due to mevalonate kinase deficiency have anemia, thrombocytopenia with/without
fluctuation, dysplasia in erythroid and myeloid lineages [47].
2.8. Malignant lymphoma
In non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients, myelodysplasia in
granulocytic and erythroid lineages were noted without any marked myelodysplasia in
megakaryocytic lineage. The myelodyspastic features were found comparable in patients with
and without bone marrow infiltration of lymphoma cells.
The bone marrow was normal or hypercellular, with normal, reduced number of erythroid
and increased number of myeloid cells, normal, or increased megakaryocytes; ALIP was not
encountered. Reticulin fibrosis was rare (6.1%).
The myelodysplasia in lymphoma was thought to be a reaction to the lymphoma or to result
from an impaired bone marrow stem cell [48].
2.9. Effect of drugs and toxins
2.9.1. Chemotherapy
Most of chemotherapeutic and immunosuppressive agents give damage to the bone marrow,
inducing megaloblastic dyserythropoiesis in low doses, and hypoplasia in high doses. Drugs
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that cause megaloblastosis are methotrexate, cyclophosphamide, daunorubicin, doxorubicin,
cytarabine, hydroxyurea, azathioprine, and zidovudine [27]. Mycophenolate mofetil is known
to cause Pelger-Huet anomaly, abnormal chromatin clumping, detached nuclear fragments in
granulocyte lineage. Alemtuzumab was also reported to be associated with increased dys‐
plastic features and virus-related hemophagocytic syndrome [27]. In our experience, the most
consistent finding of dysplasia in patients who receive chemotherapy was hypoagranulation
of myeloid cells (Figures 7 and 8).
We previously showed that leukemia patients displayed hypochromic macrocytes in their
peripheric blood due to failure to utilize iron ([49], study in submission). Additionally, serum
reticulocyte counts in the beginning of chemotherapy blocks declined significantly in the end
of the blocks when erythropoiesis was markedly depressed and were found to have increased
significantly at the beginning of the next chemotherapy block when the bone marrow regen‐
erated and erythropoiesis increased [49].
Increased apoptosis, increased hemophagocyting macrophages, erythroid and megakaryo‐
cytic regeneration generally preceding granulocytic regeneration, megakaryocytic clustering
and ALIP together with myelodysplasia were described after intensive chemotherapy and
persisted for months [27]. The infections that the patients could have developed, possibly
aggravated the myelodysplasia.
Figure 8. Neutrophils of a pediatric ALL patient while he was on maintenance chemotherapy (a, b), and 6 months after
cessation of therapy (c, d) (personal archives). Cytoplasmic agranulation (a–d), large size (a–d), chromatin clumping (b,
c), long chromatin string between the nuclear lobes (d) are striking.
On the other hand, these findings closely overlap with those in therapy-related MDS (t-MDS)
or therapy-related myeloid neoplasms (t-MN) in the new nomenclature. It was reported that
t-MN followed treatment of lymphomas and solid tumors but more rarely leukemias [101].
Appearance of new dysplastic changes after complete remission of leukemia [102] or solid
tumors should alert the physician for development of t-MN.
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2.9.2. Steroids
Steroids give rise to hyperdiploidy, and therefore macropolycytes in neutrophils [17] in
addition to abnormal nuclear lobulation (Figures 9 and 10).
Figure 9. Peripheric blood neutrophils of children who were on high dose or long-term steroid therapy for acute and
chronic ITP (personal archives). On the seventh (last) day of mega-dose methyl prednisolone therapy [116] of patient
IY (a–g, i, j, l, o) and OI (k); during the phase of tapering down long-term prednisolone therapy of patient YP (n, h, p);
6 months after the last steroid therapy in YP (m). Macropolycytes (neutrophils with >14 μm diameter) in 15–20 μm
diameter (a, c, h, m, n, p), pseudo-Pelger-Huet/like cells (a, c, j), chromatin clumping (c, f, k, n, p), bizarre nucleus (b, c,
d, e, g, j, o), vacuolated eosinophil with both basophilic and eosinophilic granules (l).
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2.9.3. Alcohol
Anemia with/without other cytopenias or pancytopenia were reported in alcohol dependent
patients. Anemia was normochromic or macrocytic with round macrocytes (unlike oval
macrocytes of megaloblastic anemia) [27, 50]. Vacuolated neutrophils, stomatocytes,
sometimes target cells were evident. In hemolytic anemia and hyperlipidemia due to alcoholic
liver disease, spherocytes, irregularly contracted cells (Zieve’s syndrome) were demonstrated
[27].
Figure 10. Various cell cycle configurations in patients with myelodysplasia (personal archives). Cell cycle analysis of
granulocytic and mononuclear cells of children with acute or chronic immune thrombocytopenic purpura (ITP) before,
during and after therapy (a–h), and granulocytes of a non-neutropenic mother of a dygranulopoietic neutropenia pa‐
tient with dysgranulopoiesis (i). Normal cell cycle of granulocytic cells (G0 phase) (a). Granulocytes of patient YP with
chronic ITP while taking oral steroids on different occasions (b, c). Mononuclear cells (d) tested on the same occasion
with (c). Granulocytes of patient AT with chronic ITP. Tested 10 days after he received anti-D therapy (e). Granulo‐
cytes of IY with acute ITP, before mega dose methyl prednisolone (MDMP) therapy (f, g); 1 week after MDMP therapy
ended (h). Granulocytes of non-neutropenic mother of a congenital dysgranulopoietic neutropenia patient who had
myelodysplasia (i).
The most striking changes in the bone marrow was in the erythropoietic lineage as erythroid
hyperplasia, ineffective erythropoiesis and dysmorphism in erythroid lineage including ring
sideroblasts (positive by 75%) and dysmorphic granulopoietic cell lineages. There was no
morphologic abnormality in megakaryocytes [50], but the megakaryocytes reportedly
increased or markedly decreased [27]. Megaloblastic changes were associated [103] and not
associated [50] with folic acid and/or vitamin B12 levels.
Serum iron levels which were elevated in the majority (being the most prominent in those with
fatty liver and typical cirrhosis), iron granules in plasma cells [50] macrophages and endothe‐
lial cells [27], large numbers of sideroblasts along with ring sideroblasts [50] were other
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characteristics of alcohol effect. In Zieve’s syndrome, excess iron-laden foamy macrophages
were encountered [27]. No correlation was found between serum iron and ring sideroblasts in
the bone marrow [50].
The normal colonies of all hemopoietic cell lines and cell culture ratios in alcohol-dependent
individuals showed that alcohol exerted its toxic effect not on committed stem cells but
peripheral cells also [50]. Reversible bone marrow aplasia due to alcohol was also reported [27].
Cytoplasmic vacuolization was reported to be due to inhibition of acetaldehyde dehydrogen‐
ase and thus reduced rate of degradation of acetaldehyde.
Alcohol has toxic effect on cell division giving rise to arrest in cell division and multinucleated
erythroblasts; direct antifolate effect on nucleic acid metabolism leading to development of
megaloblasts. Additionally, it impairs iron utilization giving rise to large number of sidero‐
blasts and ring sideroblasts through disrupting pyridoxine kinase inhibiting delta aminole‐
vulinic acid synthetase which is necessary for heme synthesis [50].
Alcohol-induced hematopoietic abnormalities closely mimick those of MDS-RARS. That
alcohol-induced bone marrow damage is always reversible if the patient stops to drink alcohol,
and that cell culture of alcohol dependent people show normal colonies of all hematopoietic
cell lines are two important points for differentiation between alcohol-induced cell damage
and MDS-RARS [50].
2.9.4. Smoking
Moderate leukocytosis being mainly due to neutrophilia and lymphocytosis was reported.
Bone marrow biopsies of 32 smokers showed normal or slightly increased cellularity, modest
and mild increase in granulopoiesis and erythropoiesis respectively, right shift of granulo‐
poietic cells (the half being mature segmented neutrophils).
The special appearing macrophages with intracytoplasmic small, polygonal corpuscles
showing neutrophils were striking. It was postulated that smoking inhibited locomotion of
the segmented neutrophils leading to granulocytopoietic hyperplasia and accumulation of
mature neutrophils in the bone marrow. These neutrophils were broken-down when they got
senescent and were phagocytosed by these macrophages, resulting in “smokers’ dysmyelo‐
poiesis” [51].
On the other hand, both smoking and alcohol intake were shown to constitute risk factors for
MDS [104].
2.9.5. Arsenic
Arsenic can cause mono-, bi-, and pancytopenia with marked dyserythropoiesis or megalo‐
blastosis. Pancytopenia with trilineage dysplasia in the bone marrow mimicking MDS was
reported. Associated symptoms like long-lasting gastrointestinal and neurological symptoms,
arsenic in the urine analysis, favorable response to British anti-Lewisite (BAL) help the clinician
distinguish between the two entities, although neurological symptoms may progress [27, 52].
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2.9.6. Lead
Lead poisoning leads to sideroblastic anemia, microcytosis in addition to basophilic stippling
and hemolytic anemia [27]. It can mimick MDS.
2.9.7. Other drugs
Isoniazid causes sideroblastic anemia. Antibiotiotic linezolid can give rise to vacuolization in
elytroid precursors and ring sideroblasts together with anemia or pancytopenia. Chloram‐
phenicol makes mild bone marrow suppression with ring sideroblasts and vacuolation in
erythroid and granulocyte precursors. Sodium stibogluconate, prescribed in leishmaniasis
causes erythroblast karyorrhexis and severe anemia [27]. Nitrous oxide (laughing gas) which
has an anesthetic and recreational use and inactivator of hydroxycobalamin may give rise to
megaloblastic anemia and vitamin B12-deficiency related neurological and hematological
effects associated with heavy use by healthcare workers who inhalate it in operating rooms or
intensive care units [27, 53].
Granulocyte colony stimulating factor (G-CSF) and GM-CSF cause neutrophil vacuolation and
dysplastic neutrophils with abnormal lobulation and development of macropolycytes, in
addition to neutrophilia, eosinophilia, toxic granulation and blasts in the peripheral blood, the
latter mimicking progression of leukemia or MDS [54]. Antiepileptic drugs also can give rise
to cytopenia and multilineage dysplasia (personal experience).
2.10. Posttransplantation
Dysplastic findings were demonstrated after solid organ transplantation, like liver, kidney,
heart, and lung. Clatch et al. [55] reported bone marrow findings of 17 liver transplantation
patients taken before or 1–1288 days after orthotopic liver transplantation (post-OLT) when
they developed mono-, pancytopenia or fever. The patients had received cyclosporine A and
prednisolone, numerous antibiotics intermittently and a few additionally received Muromo‐
nab-CD3 and/or antilymphocyte globulin.
While dysplastic hematopoiesis was completely absent from biopsies of patients with end-
stage liver disease obtained before transplantation, significant trilineage dysplasia was a
consistent finding in all patients who underwent OLT. Megaloblastic erythropoiesis, the most
characteristic finding, macrocytosis, dysynchronous nuclear-to-cytoplasmic maturation and
significant nuclear budding or bilobation were striking. Typical megaloblastic changes of the
myeloid series were absent. Dysynchronous myeloid maturation, as a left shift giving rise to
decreased bands and mature neutrophils, additionally dysmyelopoiesis and dysmegakaryo‐
poiesis were evident [55].
The authors postulated that iatrogenically-induced T-cell dysfunction in transplanted patients
which gave rise to alterations in microenvironment, direct pharmacological toxicities and the
effects of secondary infections on hematopoietic cells might have had roles in the etiology [55].
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After bone marrow or hematopoietic stem cell transplantation, bone marrow was severely
hypoplastic and after successful engraftment was achieved, all hematopoietic cells, mostly the
erythropoietic cells appeared dysmorphic. During the following months, striking and transient
increase in hematogones, mimicking leukemia was observed. During engraftment, bone
marrow architecture showed various alterations, some of which were more striking in
leukemia patients whose stromal cells had been damaged during previous chemotherapies
[27].
Secondary MDS may develop after autologous stem cell transplantation, due to previously
damaged stem cells by chemotherapy. Cytogenetic and molecular studies are useful for
distinction between secondary MDS and usual secondary myelodysplasia of early posttrans‐
plantation [27].
2.11. Other disorders with secondary dysplastic features
Multiorgan failure, autoimmune lymphoproliferative syndrome associated with Fas or Fas
ligand deficiency can give rise to secondary myelodysplasia. Hypothermia can lead to
sideroblastic anemia with recurrent thrombocytopenia [27].
3. Cases with hypoplastic bone marrow mimicking hypocellular MDS
3.1. Hypoplastic MDS and severe aplastic anemia (SAA)
In childhood MDS, RA (RCC) subgroup constitutes the majority of patients and bone marrow
cellularity was reported decreased in nearly 50% [9] and 81% [4] of children with low-grade
MDS. On the other hand, hypocellular MDS (H-MDS) in adulthood is encountered in the
elderly.
Differentiation between H-MDS/hypocellular RCC and AA may be challenging both in adults
and children.
There are many nonhematological factors that can give rise to bone marrow hypoplasia in
childhood like any type of infections (vitamin deficiencies, metabolic disorders like mevalo‐
nate kinase deficiency, rheumatic disease, mitochondrial deletions (Pearson syndrome)).
Moreover, there are many hereditary or nonhereditary hematological disorders that should
be differentiated from RCC in the setting of hypoplastic bone marrow like inherited bone
marrow failure syndromes [4].
The most recent histopathologic criteria to distinguish RCC from SAA in childhood is
presented in Table 7 [14, 57].
In adulthood, a similar study described standardized criteria to distinguish hypocellular AML
from H-MDS and aplastic anemia (AA) (Table 8) [59].
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Refractory cytopenia of childhood (RCC) Severe aplastic anemia (SAA)
Differences  1. Erythroid lineage
-Patchy distribution (clusters consist of ≥10
erythroid precursors)
-Maturation arrest
-Increased mitosis
-Increased proerythroblasts (left shift)
1. Erythroid lineage
-Missing or a single and small cluster
-Clusters consist of <10 erythroid cells
-Erythroid cells with maturation
2. Granulocytic lineage
-Marked decrease
-Left shift
2. Granulocytic lineage
-Missing or marked decrease
-Very few clusters of granulocytes with maturation
3. Megakaryocytic lineage
-Marked decrease
-Micromegakaryocytes
-Dysplastic findings
3. Megakaryocyte lineage
-Missing or very few
-No dysplastic changes
-No micromegakaryocytes
Similarities 1. Lymphoid lineage
-May be increased focally or dispersed
1. Lymphocyte lineage
-May be increased focally or dispersed
2. CD34+ cells
-No increase
2. CD34+ cells
-No increase
Table 7. Histopathologic criteria for differential diagnosis of SAA and RCC [4, 14, 57, 105].
Manifestation Indicative of
Presence of unequivocal blasts in the peripheral blood MDS or AML
Hypogranular neutrophils or pseudo-Pelger neutrophils (>10%) MDS or AML
Presence of >1–20% blasts in the bone marrow + dysplasia MDS
Dysplasia of either granulocytes or megakaryocytes in the bone marrow
(if erythroid hyperplasia is the sole finding, dysplasia in erythroid lineage
should be moderate to severe)
Inconsistent with AA
Presence of any abnormal sideroblasts (>5 granules around the nucleus
or constituted at least 1/3 of the circumference
Excludes AA
1–2 cm core biopsy demonstrating four to five undistorted fields (×100 magnification) Reliability in diagnosis
Presence of two or more clusters of immature precursors (being minimum three blast per
cluster) in bone marrow biopsy
MDS or AML
Consensus diagnosis required by at least 5/7 participants Reliability in diagnosis
Table 8. Recommendation for standardized approach to distinguish hypocellular AML from hypocellular MDS and
AA [59].
In addition to the parameters listed in Tables 7 and 8, presence of ALIP, abnormal localization
of megakaryocytes, erythroblast clusters, fibrosis, abnormal karyotype were also reported as
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parameters to be used to distinguish H-MDS and SAA (Table 8) [59]. Nevertheless, further
studies are needed to examine the validity of histopathologic approach to hypocellular RCC
and AA [60].
3.2. Inherited bone marrow failure (IBMF) disorders in the differential diagnosis of
hypocellular RCC
Several children who are diagnosed with hypoplastic RCC, may actually have one of inherited
bone marrow failure (IBMF) disorders which have not been diagnosed yet. Hence, 15% of
patients diagnosed with hypoplastic RCC and 2, 5, and 10% of patients diagnosed with
hypoplastic RCC or aplastic anemia were later diagnosed as Fanconi anemia and heterozygous
or homozygous dyskeratosis congenita [4, 9]. Inherited bone marrow failure syndromes with
pancytopenia like Fanconi anemia, dyskeratosis congenita, Shwachman Diamond syndrome,
amegakaryocytic thrombocytopenia (in progression), and pancytopenia with radio-ulnar
synostosis display common manifestations with hypoplastic RCC, such as macrocytosis,
elevated HbF, common bone marrow features. Therefore, a careful family and past history,
physical examination is essential. Laboratory and molecular studies like chromosome break‐
age test and telomere length assay should be carried on, since not all children with IBMF
syndromes have phenotypic characteristics [4, 9]. These diseases can progress to MDS gaining
chromosomal abnormalities specific to MDS and 3q26 segment in Fanconi anemia. However,
abnormal clones can also regress in any IBMF syndrome [4].
In childhood, in the setting of hypocellular bone marrow with absence of cytogenetic abnor‐
mality [4] or a bone marrow biopsy with topography and cellularity of the local hematopoiesis
[9], two bone marrow biopsies at least two weeks apart are necessary [4].
4. Transient chromosome abnormalities in the setting of cytopenia/
spontaneous remission in MDS
4.1. Transient MDS with/without chromosomal alterations
Monosomy 7 is an harbinger of poor prognosis and higher risk of transformation to high-risk
MDS and AML [4, 61–67, 69, 70] than other chromosomal abnormalities and normal karyotype
[4, 105]. The estimated time of progression in children with monosomy 7 was reported as
1.9 years, with a cumulative progression incidence of 80% at the sixth year of diagnosis [4].
In the literature, we found 13 patients who presented with MDS (n:12) or MDS-like features
(n:1) and had genetic abnormalities but achieved remission only after symptomatic (n:12) and
vitamin B12 and folic acid (n:1) therapies. The patients had abnormalities of chromosome 7 (12
out of 13, as −7, −7q, i7) and 11q23 translocation (1 out of 13), and +21 (1 out of 13, coexistent
with −7). Two additional MDS patients (RA, RAEB) with normal karyotype achieved sponta‐
neous remission (Table 9).
Spontaneous disappearance of abnormal clones were reported previously in AML, EBV-
associated myeloproliferative disorder and Fanconi anemia [65]. Development of cytogenetic
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abnormality is only one step (first hit) in the progression of malignant clone. In order to gain
growth advantage, the transforming cells need other molecular changes within the cells and
in the marrow microenvironment (second hit). The cases who attained spontaneous remission
suggest that the development of cytogenetic abnormality might have not been supported by
the other cellular and microenvironmental changes [65, 66]. Additionally, the mutation may
have developed in a hematopoietic cell with limited self-renewal capacity and may not have
involved the whole stem cell pool [66]. Two cases of Bader-Meunier et al. [68] suggest that
patients with MDS who do not show any chromosomal abnormality can also achieve complete
remission (Table 9). These cases show that patients who are stable should be closely observed
for some time before potentially toxic therapies are started.
Cases Diagnosis Age/
sex 
Genetic analysis  Management  of
therapy 
Outcome
/time
elapsed to
hematologic
/cytogenetic
complete
remission
(hem/cyto
rem) (months)
Duration of
follow-up
after cyto
rem
attained
(months)
Reference
1 De novo
MDS† 
8/12,
M
45,XY,−7 [12] Transfusions <2 years
(hem + cyto
rem)
108 months  [61]
2 De novo
MDS† 
15/12,
M
46,XY [13]/45,XY, −7 [7] No 8 months
(hem + cyto
rem)
14 months [61]
3 t-MDS† (after
completing
rabdomyo-
sarcoma
therapy)
10.5,
M
46,XY,del (7)(q22q32) [4]
(out of 40 metaphases)
No 5 months
(hem + cyto
rem, hem rem
partial)
95 months [61]
4 t-MDS† (after
completing
medullo-
blastoma
therapy)
8/M 46 XY,del(7)(q31q36) [5]/46,
XY,+der(1)t(1;7)(p11.2;p11.2),
-(3)/46,XY,+dic(1;21)
(p11.2;p11.2),
−21 [4] and other anomalies
ivIgG and
transfusion
4 weeks (hem
recovery; cyto
rem
unknown©)
67 months [61]
5 RAEB 14/12,
M
46,XY [13]/45,XY, −7 [7] Transfusions
/BMT planned
13 months
(hem + cyto
rem)
21 months [62]
6 t-MDS†
(Spina bifida,
ESRF* ; AZA
therapy**
19, F 45,XY, −7 [5] (out of 62
metaphases)
AZA stopped,
transfusions
17 months
(hem + cyto
rem)
NS# [63]
7 t-MDS†*** after
completing
Hodgkin’s
disease therapy
15, F 45, XY, −7 [19] (out of 20
metaphases)
NS#
BMT planned
10 months
(hem + cyto
rem)
NS# [64]
8 t-MDS† (after
completing
Ewing sarcoma
therapy
19, M 46,XY,(11;16)(q23;p13.3) [13]
(out of 20 etaphases)
NS#
BMT planned
12 months
(hem + cyto
rem)
NS# [64]
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Cases Diagnosis Age/
sex 
Genetic analysis  Management  of
therapy 
Outcome
/time
elapsed to
hematologic
/cytogenetic
complete
remission
(hem/cyto
rem) (months)
Duration of
follow-up
after cyto
rem
attained
(months)
Reference
9 De novo
MDS† 
13/12,
F
46,XX,i(7)(q10) [3]/46,XX [11] NS# 10 weeks
(hem + cyto
rem)
NS# [65]
10 De novo
MDS† 
3, M 45, XY, −7 [8] (out of 12 cells) No BMT planned 30 months
(hem + cyto
rem)
>80 months  [66]
11 Pancytopenia
bilineage
dysplasia
mimicking de
novo MDS‡
7.5, MComplex karyotype
including
del(7)(q11) (in 3 out of
21 cells):
*58,XY,+2,+3,+6,+inv(7)
(p13p22),del(7)
(q11),+10,+11[1]
* + 15,+17,+18,+19,+20,+22:46,
XY,del(7)(q11)[1]* 45,XY,
del(7)(q11), −18 [1]
(+chromatid, isochromatid
breaks)
VB12 and folic
acid therapy due
to their deficiency
4 weeks
(hem + cyto
rem)
NS# [67]
12 RA 8, F Normal (46,XX)
[cell no NS# ]
No Hem rem:
NS# 
Nearly
72 months
[68]
13 RAEB 3mo,
F
Normal (46,XX)
[cell no NS# ]
No Hem rem:
NS# 
Nearly
66 months
[68]
14 Donor cell-
derived MDS
after cord blood
transplantation
(+3 mo) for
AML secondary
to ALL†
4, F 46 XY,-7 [cell no NS# ];
full donor chimerism;
no genetic
abnormality in the
cord blood
and the donor
Transfusions Nearly 24 mo
(hem + cyto
rem)
NS# [69]
15 Aplastic
anemia on
intravenous
cyclosporine
and androgen
therapy
21,M 47,XX, −7,+21,+mar
[cell no NS]
Drug switched to
oral form. Then
abnormality
disappeared
Hem
improvement
as transfusion
independence;
cyto rem
Minimum
6 months
[70]
†The subgroup has not been reported. Probably corresponds to RCC subgroup in childhood and RCMD or MDS-U
subgroups in adulthood MDS, according to the WHO 2008 classification.
©Cytogenetic abnormality found sustained on 13th month after hematologic recovery.
*End-stage renal failure.
**The patient received long-term immunosuppressive therapy with cyclosporine (for 19 months), later azacytidine
(Aza) (for 6 years).
#Not stated.
***The patient had pancytopenia persisting after the 1st course of Hodgkin’s disease therapy.
Table 9. Patients with MDS who achieved remission spontaneously, after supportive or vitamin B12 and folic acid
therapy [61–70].
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4.2. Vitamin B12 (VB12) and folic acid deficiency and transient chromosome abnormalities
which mimick MDS
Vitamin B12 and folic acid deficiencies can present as mono-, bi-, and pancytopenia [106],
myelodysplasia, genetic abnormalities like increased frequency of spontaneous chromosome
breakage and centromere spreading [107, 108], elongation and despiralization of chromosomes
[107], multiple rearrangements and deletions of different chromosomes [108] which can
mimick that of MDS (Table 9, patient 11) [67].
Many of these chromosomal abnormalities were reported to reduce [107], completely disap‐
pear [67, 107, 108] or persist up to 6–12 months after hematological remission was attained
[107] after therapy.
These cases show that defective synthesis and repair of DNA which were reversed by VB12
and folate plays role in the pathogenesis of genetic abnormalities in megaloblastic anemia.
Increased immature myeloid cells indistinguishable from myeloblasts in the bone marrow of
patients with vitamin B12 and folate deficiency make the differentiation between megaloblastic
anemia and MDS more difficult [109].
On the other hand, in our clinics, we have encountered considerable number of patients who
had VB12 and/or folic acid deficiency coexistent with MDS or leukemia.
5. Mutations in the elderly and other cases
In more than 10% of healthy people older than 70 years, clonal hematopoiesis is present [10].
Additionally, loss of Y chromosome in hematopoietic cells in association with aging was also
reported [1]. Therefore, clinicians should keep reserved when abnormalities in molecular
genetics and karyotype are found in the elderly when dysplasia is absent [10].
Mutations like del(20q), +8, −Y have been reported in patients with aplastic anemia or other
cytopenic syndromes who were good responders to immunosuppressive therapy and/or no
evidence of MDS findings in the follow-up [1].
6. Acute myeloblastic leukemia
6.1. AML with low blast cell count
AML is distinguished from MDS by the percentage of the blasts which is higher than 30% in
AML in children (>20% in adults) and lower than 30% (lower than 20% in adults) in MDS.
However, patients that have blast cells lower than 30%, but cytogenetic features characteristic
of childhood de novo AML [t(8;21), inv(16), t(11;17), t(9;11), i(1)] is designated as AML with
low blast cell count (AML-LBC).
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Those with AML-LBC were significantly younger than MDS cases (3.7 vs 7.4); their dysplasia
score was lower and the response to AML type chemotherapy was higher than that of MDS
patients. The authors encountered chloroma only in AML-LBC [71].
6.2. AML with myelodysplasia-related changes (AML-MRC)
In a subgroup of leukemia that was introduced by WHO is AML with myelodysplasia-related
changes (AML-MRC) which defines AML arising from previous MDS or MDS/MPN, with an
MDS-related cytogenetic abnormality and/or AML with multilineage dysplasia (AML-MLD).
This group was reported to have worse overall survival when compared with patients with
AML-not otherwise specified [110].
6.3. MDS with myelofibrosis, AML-M7, and other disorders
The blast cell percentage in the bone marrow (>30% in children and >20% in adults) and t(1;22)
(p13;q13) differentiated AML-M7 from MDS.
Although hypoplastic MDS with increased reticulin ± collagen fibers is rare in childhood [4],
hypoplastic myelofibrosis may be encountered in childhood [111].
7. Idiopathic cytopenia of undetermined significance (ICUS) and
idiopathic dysplasia of undetermined significance (IDUS)
Patients with persistent (marked constant) cytopenia(s) involving one of more hematopoietic
lineages, for at least 6 months, in the setting of absent multiunilineage dysplasia and cytoge‐
netic abnormality except –Y, +8, del(20q) were suggested to be termed as idiopathic cytopenia
of undetermined significance (ICUS) [5, 58, 112–116]. Criteria of cytopenia for diagnosis of both
MDS and ICUS according to the 2007 Consensus Group are: Hemoglobin (Hb) <11g/dl and/or
neutrophils <1500/mm3, and/or thrombocytes <100,000/mm3. The cut off levels for Hb is
10 g/dl, for neutrophils 1800/mm3 according to WHO and International Working Group on
Morphology of MDS (IWGM-MDS) [58, 114].
The terms “ICUS-anemia, ICUS-neutropenia, ICUS-thrombocytopenia, ICUS-bicytopenia, or
bi/pancytopenia” were also proposed in which the cut-off levels of cytopenia were the same
of those in 2007 Consensus Group, except that of neutropenia which was proposed as
<1000/mm3 [114].
For patients with morphological dysplasia (>10% in a major cell line) with/without karyotypic
abnormalities but no or mild cytopenia, idiopathic dysplasia of undetermined significance
(IDUS) has been proposed [5, 7]. Criteria of mild cytopenia has been reported as Hb ≥ 11 g/dl,
neutrophils ≥ 1500/mm3, thrombocytes ≥ 100,000/mm3 [113] (Table 10).
Patients with both ICUS and IDUS may progress to overt MDS, MPN, MDS/MPN overlap
disease, chronic myelomonocytic leukemia, AML after a variable period. ICUS can also
reportedly transform to systemic mastocytosis, non-Hodgkin lymphoma, aplastic anemia [5,
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113, 114]. There is no proof that every patient with ICUS or IDUS will develop neoplasia [114].
ICUS was reported to resolve spontaneously also [112]. However, the median overall survival
in ICUS group was reported 44.3 months, being shorter than RA but longer than RCMD [116].
Idiopathic cytopenia of unknown
significance (ICUS)
Idiopathic dysplasia of unknown
significance (IDUS)
Constant marked cytopenia* Present [5, 58, 112–116] Absent [5, 58, 112–116]
Diagnostic criteria of MDS Absent [5, 58, 112–116] Absent [5, 58, 112–116]
Diagnostic cocriteria of MDS**,† Absent [113]; flow cytometric abnormalities:
not known [112]
–?
Dysplasia (>10% of cells) Absent [112–115] Present [112–116]
Karyotype typical for MDS Absent but FISH may reveal a very small
clone carrying MDS-related cytogenetic defect
[113, 114]
Present in a minority [112]
Clonality by HUMARA In a minority of patients [112] (CCUS) Not known [112]
Other diseases leading to
cytopenia
No [113] –
Other diseases leading to
dysplasia
– No [113]
Age Older [113] Younger [113]
Erythropoietin level Low [113] Adequate [113]
Marked reduction in BFU-E In a minority of patients [112] In a minority of patients [112]
Ring sideroblasts >15% Absent [114] In a majority of patients [114]
*Cytopenia in one or more of hematopoietic lineages lasting for at least 6 months, with Hb <11 g/dl and/or neutrophils
<1500/mm3, and/or thrombocytes <100,000/mm3.
**Cocriteria of MDS: Colony forming cells and reticulocytes in circulation, abnormal immunophenotyping by flow
cytometry, monoclonality of myeloid cells detected by molecular markers or mutations, abnormal gene expression
profile by mRNA profiling assays.
†If one or more cocriteria are found, the disorder should be called ‘highly susceptive for a clonal myeloid disease/MDS’
[113].
Table 10. Diagnostic criteria for ICUS and IDUS [5, 58, 112–116].
On the other hand, recent reports demonstrated that ICUS had a broad spectrum including
patients with both nonclonal and clonal hematopoiesis, the latter being called as clonal
hematopoiesis of indeterminate potential (CHIP) [112]. Hence, 35% of ICUS patients were
found to carry a somatic mutation or chromosomal abnormality indicative of clonal hemato‐
poiesis [117] called clonal ICUS (CCUS).
Differentiation between MDS and ICUS may be challenging. In ICUS, FISH may reveal a very
small clone carrying MDS-related cytogenetic defect [113, 114]. Clonal expansion of such a
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small clone in ICUS and occurrence of slight cytopenia in IDUS in the follow-up, points at an
imminent transformation to MDS [58, 113, 114].
These patients should be examined regularly, like in low-risk MDS, from the aspect of
hematological findings, karyotype, FISH, flow cytometry, and flow FISH, if available [114].
Reduced number of colony forming unit (CFU) progenitor cells like CFU-granulocyte-
macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E) show impaired bone
marrow function in MDS [58]. While BFU-E is markedly reduced in MDS, it is reduced only
in a minority of patients with ICUS and IDUS [114]. However, reduced numbers of CFU-GM
and BFU-E are also found in aplastic anemia, acute leukemia, and in post chemotherapy
conditions, but not in nonclonal cytopenias like vitamin B12 deficiency, autoimmune hemo‐
lytic anemia and chronic inflammation [58] (Table 10).
Screening for molecular lesions by exome sequencing and other “omics-based techniques” can
be used, in order to search clonality. However, these techniques are expensive and not practical
[58]. Human androgen receptor gene-based assay (HUMARA) which is promising has
restrictions, since it can be used only in females and it is positive in other clonal disorders also
[58, 116]. Application of flow cytometric tools are of considerable help [58] (see Section 10).
Patients with CCUS can be differentiated from low-risk MDS only by lack of dysplasia [112].
The data about patients with ICUS, CCUS, and IDUS are limited. Future studies will enlighten
the pathogenesis of ICUS and IDUS which is not well understood yet.
8. Autoimmune disorders
Patients with chronic immune stimulation and autoimmune disorders have a tendency to
develop malignant neoplasias and MDS.
On the other hand, MDS and AML can trigger paraneoplastic syndromes and manifestations
including inflammatory paraneoplasia, like seronegative rheumatoid arthritis, Sweets
syndrome, hemophagocytic lymphohistiocytosis, pyoderma gangraenosum, cutaneous
vasculitis, lupus-like symptoms [72, 73], polychondritis [73], Behçet syndrome, inflammatory
bowel disease, cryoglobulins, vitiligo, autoimmune hemolytic anemia, peripheral neuropathy,
by 12–19% in adults but in lower frequency in childhood [74].
Relevance of autoimmune disorders with prognosis of MDS is disputable. Their response to
immunosuppressive therapy is good [72].
In MDS, not only the stem cells but an inflammatory microenvironment is also involved.
Therefore, the inflammatory microenvironment aggravates ineffective hematopoiesis and
carcinogenesis/tumorigenesis [72].
The majority of acquired AA and some RCC cases can be considered as T-cell-mediated
autoimmune disease, resulting in bone marrow failure [74, 76]. Autoantibodies are detected
in both conditions. However, their significance and pathophysiological significance in MDS
and SAA is unclear [76].
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Relative lymphocytosis, oligoclonal T-cell expansion, elevated cytokine levels are common
features of AA and MDS, suggesting a common immune defect in the pathogenesis [72] of
adults with low-grade MDS.
Decreased CD4 + FOXP3 + Treg cells, increased NK cells/impaired activity of NK cells,
suppression of hematopoietic progenitors by cytotoxic CD8+ cells [72, 74], increased cytokines
secreted by bone marrow microenvironment, macrophages (IF-  , TNF-α which are pro-
apoptotic), increased Th17 cells [interleukin ((IL)-17, IL-23, IL-1, and IL-6] which are cytotoxic
to bone marrow precursors, decreased dendritic cells, decreased B cells [72], polyclonal hypo-,
hypergammaglobulinemia, C3 hypocomplementemia, altered self-reactive antibody reper‐
toires [74] play role in the pathogenesis, some of which change as to the risk of MDS [72].
Some of these abnormalities overlap with those in autoimmune disorders themselves. The
dysmorphic features in autoimmune disorders were delineated previously. Patients with
autoimmune disorders should always be suspected for being MDS cases and should be
evaluated for pathologic and genetic abnormalities.
9. Common features in pathogenesis
9.1. Cytopenia
Inherited bone marrow failure syndromes, MDS and SAA share the same pathogenetic
features for involving a driver mutation, overproduction of cytokines and/or suppression of
hematopoiesis through cytokines and deregulation of stem cell niche [76].
MDS and severe aplastic anemia share the same pathogenesis, as to abnormalities in T cells,
especially in CD8+ cells; autoimmune manifestations and giving good response to immuno‐
suppressive therapy [76].
9.2. Myelodysplasia in relation to cell cycle and other factors
Myelodysplasia in blood cells arise due to any challenge during the course of normal differ‐
entiation in which cells exit the cell cycle and enter G0 phase permanently (Figure 10a)
Cell cycle control system depends on cyclically activated cyclin-dependent protein kinases
(Cdks) a number of enzymes and other proteins, the most important being cyclins and other
genes [118]. Stem cell differentiation is regulated by differentiation specific genes, homeotic
genes, tumor suppressor genes, abnormality of which result in restriction in further prolifer‐
ation giving rise to alteration in normal cell cycle, and dysdifferentiation [119].
Hence, disturbance of expression of iron dependent genes regulating cell cycle in differentia‐
tion of hematopoietic cells in iron deficiency (see Section 2.5.2), deletion in human cell division
cycle related gene (hCDCrel) in patients with del (22q11.2) are a few examples that lead to
aforementioned myelodysplastic findings through genetic abnormalities. That the severity
and spectrum of dysmorphic features in myelodysplasia differ according to the underlying
secondary or primary pathology like in dysmegakaryopoiesis and thrombocytosis in inv
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3(q21q26)/t(3;3)(q21;q26) and 5q-syndrome also reflect the various alterations playing role in
different levels of differentiation.
We previously detected various temporary or permanent cell cycle abnormalities in total
leukocytes, granulocytes and mononuclear cells from peripheral blood of ITP patients who
had received steroids and a child with congenital neutropenia and her non-neutropenic mother
all displaying myelodysplasia (Figure 10) [17, 45, 99].
The peripheral granulocytes (neutrophils and bands), monocytes, and lymphocytes are
expected to be in G0 phase of the cell cycle, since they are terminally differentiated (Fig‐
ure 10a). We interpreted these numerous abnormal cell cycle configurations instead of G0 [99],
as an alteration in differentiation, after a stimulus that was sensed as DNA damage, probably
through disruption of one or more of these aforementioned enzymes [118]. Increased trilineage
apoptosis, a type of cell death in some of these patients [45, 99], all having myelodysplasia are
also in accordance of this interpretation.
Overlapping of a number of myelodysplastic features (Tables 1–4) closely with those of
senescence-like phenotype (SLP) of rapid cell senescence (RCS), another type of cell death, led
us to search RCS both in congenital neutropenia [45, 99] and autoimmune disorders (JRA, SLE,
and ITP) all having myelodysplasia [17, 28, 30, 31, 79]. We detected that three children with
congenital neutropenia and their non-neutropenic mothers [45, 99] and all patients with
autoimmune disorders displayed RCS in their leukocytes shown by β-galactosidase (SA-β-gal)
positivity [79] (Figure 1). In several patients, cell cycle abnormalities accompanied [99]
(Figure 10I).
The RCS that was detected in autoimmune disorders and those with congenital neutropenia
[45] were attributed to increased proinflammatory cytokines and chemokines in autoimmune
disorders [79] and congenital neutropenia [45] through giving rise to loss of telomeres by
keeping the immune system in a state of low level of activation [79]. Absence of RCS (unpub‐
lished data) in iron deficient patients was thought to be due to absence of increase in proin‐
flammatory cytokines, confirming this hypothesis.
Differentiation is controlled not only by intracellular genetic factors but by extracellular factors
like extracellular matrix and soluble factors like fibroblast growth factor (FGF), transforming
growth factor beta (TGFB), colony stimulating factor-1 (CSF-1), GCSF, GM-CSF, stem cell factor
(SCF), Fms-like tyrosine kinase 3 ligand (Flt-3 ligand), ILs as well [119].
The reasons that we previously discussed in secondary myelodysplasia like immune destruc‐
tion of stromal and hematopoietic cells, inhibitory effects of cytokines and/or other intracel‐
lular/extracellular messengers/soluble factors, on the microenvironment and/or hematopoietic
cells; decreased differentiation, regeneration and increased clearance of stem cells, reflected
by alterations in cell cycle, impairment of heme synthesis and iron utilization also play role in
dysdifferentiation.
Therefore, myelodysplasia either primary or secondary is associated with cell death parame‐
ters, and cell cycle alterations. It reflects the viability of the cell and can be assumed as a tip of
a big iceberg that is an harbinger of a large spectrum of primary (clonal) and secondary
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(nonclonal) disorders. We think that the criteria of dysplasia should be revised in the definition
of MDS and attention should be exercised to find out practical laboratory means to detect
clonality.
10. Differential diagnosis
Discrimination between low-risk MDS and disorders mimicking MDS depends on determin‐
ing whether hematopoiesis is clonal or not.
To assess clonality and dysplasia, flow cytometric evaluation is promising [58, 120, 121]. The
minimal requirements to assess dysplasia by flow cytometry have been defined for adulthood
low-risk MDS as in the following [120]:
(a) For immature myeloid and monocytic progenitors: Increased percentage of cells in
nucleated cell fraction, lack of/decreased/increased expression of CD45, CD34, CD13 + CD33,
homogenous under/overexpression of CD117, lack of/increased expression of HLA-DR,
asynchronous expression of CD11b, CD15, expression of CD5, CD7, CD19, CD56 which are
lineage infidelity markers.
(b) For maturing neutrophils: Decreased percentage of cells as ratio to lymphocytes, sideward
light scatter (SSC) as ratio vs SSC of lymphocytes, altered pattern in relationship of CD13 with
CD11b and CD13 with CD16, CD15 with CD10 (like lack of CD10 on mature neutrophils).
(c) For monocytes: Decreased or increased percentage of cells, shift toward immature distri‐
bution, altered pattern in relationship of HLA-DR with CD11b and CD36 with CD14, homo‐
genous under or overexpression of CD13 and CD33, expression of CD56 as which is a lineage
infidelity marker.
(d) Progenitor B cells: Decreased or absent progenitor B cells when enumeration is performed
as fraction of total CD34+ based on CD45/CD34/SSC in combination with CD10 or CD19.
(e) Erythroid compartment: Increased percentage of nucleated erythroid cells, altered pattern
in relationship of CD71 with CD235a, decreased expression of CD71 and CD36, increased
percentage of CD117-positive precursors.
(f) For megakaryocytes: No standard application of flow cytometry has been described for
megakaryocytes yet.
World Health Organization recognized more than three flow cytometric aberrancies as
indicative of MDS [120]. It was also reported that two or more aberrancies in only the four
parameters as increased percentage of CD34+ progenitor cells in bone marrow, decreased
number of progenitor B cells within the CD34+ compartment, decreased or increased CD45
expression on myeloid progenitor cells and decreased SSC of neutrophils, CD10, CD15, CD11b,
CD56 being additional useful markers could identify 70% of low-risk MDS cases with 94%
specificity [120]. In children, for distinction between SAA and RCC, which generally present
with hypocellular bone marrow, a cutoff of 2 flow cytometric abnormalities was found to have
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60% sensitivity and 88% specificity which changed as 76% and 84% respectively, when
combined with other diagnostic parameters [121]. In nonclonal disorders either no or only one
flow cytometric abnormality was found. In low-risk MDS, in rare patients no flow-cytometric
abnormality was found [58].
However, abnormal flow patterns were encountered in AML, MPN, and natural aging also
[58]. Current knowledge on normal and abnormal patterns in the elderly and in normal
controls is still inadequate [120].
The flow cytometric analysis of children with RCC (low-risk MDS in childhood) showed no
difference in the relative SSC of granulocytes between those in RCC and healthy controls and
absence of lineage infidelity markers on myeloid blasts unlike commonly occurring in adult
low-risk MDS. The most frequent abnormality in RCC was reported to be heterogeneous
expression of CD71 and CD36 on erythrocytes and aberrant expression of CD56 on monocytes
(in 58 and 20%). All other abnormalities were observed in RCC in lower frequency than in
adulthood low-risk MDS [121].
However, although flow cytometric evaluation is promising in diagnosis of MDS cases which
lacked specific diagnostic markers like ring sideroblasts or karyotypic aberrations, it can only
be used as a part of a diagnostic work-up consisting of histopathology and cytogenetic analysis
[120, 121].
Flow cytometry can be used to rule out PNH; but minor PNH clones are present in 13–23% of
adult MDS, and 41% of children with RCC [121].
11. Future recommendations
We recommend that all the aforementioned disorders be considered in the differential
diagnosis of MDS. Patients who do not comply with none of a definite diagnosis should be
followed-up for a considerable time period in order to assure a spontaneous remission or
progression. Spontaneous remission in children and youngsters were reported as 2.2–30
months after the diagnosis [61–68]. In childhood, in the setting of hypocellular bone marrow
with absence of cytogenetic abnormality [4] or a bone marrow biopsy with topography and
cellularity of the local hematopoiesis [9], two bone marrow biopsies at least two weeks apart
are necessary [4]. For cases with refractory cytopenia and cases with less than 15% ring
sideroblasts all of which display unilineage dysplasia without excess blasts, repeated bone
marrow examination is recommended after a 6 months’ observation [5].
Since morphologic dysplasia can be encountered in both clonal and nonclonal disorders, the
criteria of dysplasia should be revised in the definition of MDS and attention should be
exercised to find out practical laboratory means to detect clonality. Flow cytometry is a
promising means to distinguish between clonal and nonclonal cytopenia when used together
with other diagnostic tools.
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